Degradation of proteins by the ubiquitin-proteasome system (UPS) is an essential biological process that eukaryotic cells use to regulate their functions and coordinate their signaling networks. In particular, it plays a crucial role in neuronal development regulating very important functional and morphological interplays of neurons, such as synaptic plasticity, neurotransmitter release and morphogenesis of axons. Pathogenic alterations of genes involved in the proteolysis by UPS have been associated with several neurodevelopmental disorders (NDDs) and human diseases, highlighting the importance of this regulatory mechanism to developmental processes and neurogenesis.
Introduction
Neurodevelopmental disorders (NDDs) are a group of clinically and genetically heterogeneous disorders, diagnosed during early childhood, including intellectual disability (ID), autism spectrum disorders (ASD), communication and learning disorders, attention deficit/hyperactivity disorders (ADHD) and motor disorders. They have an estimated prevalence of approximately 1% and represent one of the major challenges in medicine being the most frequent causes of disability in children (nearly 3 of 100 babies are affected) and the main reason for referral in clinical genetic centers. Furthermore, incomplete penetrance and variable expressivity can influence their inheritance, and thus represents a challenge for genetic counselling [1] . In the last fifteen years [2] , the identification of underlying genetic defects and risk factors for NDD have increased significantly due to the development of new diagnostic technologies like Next Generation Sequencing (NGS) and Chromosomal Microarray Analysis (CMA). This allowed many affected patients, who had previously undergone many invasive, expensive, and uninformative tests, to receive a definitive genetic diagnosis. Up to date, mutations at over 1000 loci have been associated with NDDs [3, 4] .
Among them, the activity impairments of genes involved in the proteolysis by the ubiquitin-proteasome system (UPS) has been demonstrated for some distinctive clinical entities such as Angelman Syndrome (UBE3A, MIM:601623) [5] , Kaufman oculocerebrofacial syndrome (UBE3B, MIM:608047) [6] , X-linked Turner-type syndromic mental retardation (HUWE1, MIM:300697) [7] , chromosome 16p13.2 deletion syndrome (USP7, MIM: 602519) [8] , mental retardation, X-linked 99 and mental retardation, X-linked 99, syndromic female-restricted (USP9X, MIM: 30072) [9] . More recently another gene, PSMD12 (Proteosome 26S Subunit Non-ATPase, 12;
OMIM 604450), encoding for a non-ATPase subunit of the 19S regulator of the 26S proteasome complex, has been implicated in the etiology of an emerging syndromic form of NDD characterized by ID, motor and speech delay, abnormal behavior, hypotonia, craniofacial, cardiac, renal, skeletal and genital abnormalities. Other clinical features, less frequently reported, are seizures and brain structural abnormalities [10, 11] .
Herein, we report on the first patient with a missense variant in PSMD12, who showed ID, speech delay, abnormal behavior, and dysmorphic features. Modeling its impact on the three-dimensional structure demonstrate disturbance 
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on the protein stability. We compared the clinical features of our patient to the previous reports founding strong clinical correlation in the phenotype.
Case Presentation
The patients was a 19-year-old male referred for genetic counseling due to ID, congenital malformation, facial dysmorphisms with delayed speech and language development. The proband was the second male child of apparently healthy, non-consanguineous Italian couple with not known family history of neurological abnormalities, recurrent miscarriages, other birth defects and/or genetic illnesses. The proband was delivered at term (38 weeks of gestation) by programed cesarean section. The pregnancy was characterized by contractions at 7 th month of gestation, otherwise passed uneventful. The birth weight of 3,800 kg (90 th centile), length of 50 cm (75 th centile), and head circumference of 32 cm (5 -10 th centile). APGAR scores were 9/10 at 1 st and 5 th min, respectively.
Important data from anamnestic history: at age of 5 years the patient had chirurgical intervention for hypospadias; at age of 12 years the patient had dental chirurgical intervention for multiple unerupted teeth with unusual position (12 palatal teeth). Furthermore, during dentist controls misalignment of teeth and gemination were observed; treatment for scoliosis and flatfoot have been undertaken during development; ophthalmological correction for strabismus has been done; presence of multiple nevus on whole body is under dermatological control and regular follow up; no treatment for short stature. He also had a history of development delay (the first stepswalking at 18 months; first words at 24 months), learning problems and still requires learning support at school. The proband was evaluated in our medical genetics unit during the first visit at the age of 19 years. On examination his height was 185 cm (75-90 th centile), weight was 65 Kg (25-50 th centile) and occipital frontal circumference (OFC) was 57 cm (90 th centile). A distinctive facial appearance was noted with elongated and hatchet face, bitemporal hollowing, thick eyebrow with synophrys, down slanting palpebral fissures and eyelids ptosis, long and prominent nasal bridge, low-set and posteriorly rotated ears, high arched palate, triangular chin with micrognathia, webbed neck, low hairline at the back of the neck (Figure 1 ). In addition, the patient showed pectus excavatum, prominent scoliosis, relative joint hyper extensibility and bilateral pes planus. 
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The proband had no reported seizures. In medical documentation, presented during genetic counseling, the results of routine hemato-chemical laboratory examination (hepatic, renal, hormonal, martial) were normal. ORL examination within normal limits. Ophthalmological examination: OO +1.75 sf. Strabismus. Normal male karyotype (46, XY) was observed; high resolution SNP array analysis, performed by using CytoScan HD Array (Affymetrix, Santa Clara, CA) as previously described [12] did not identify any pathogenic copy number variations (microdeletions or microduplications) in the patient; 5'UTR FMR1 resulted in normal allele (31 ± 1CGG ripetitions). On the basis of genetic counseling, objective examination, taking in consideration all possibilities of differential diagnosis and clinicians suspect was decided to perform further genetic tests by implementation of NDD gene panel, after pre-test counseling and obtaining of written informed consent. December 2016), HRC [17] , Kaviar [18] and ClinVar [19] . Missense variants were further annotated by dbNSFP ver. 3.2 from which we retrieved pre-computed pathogenicity predictions and evolutionary conservation measures [20] .
Materials and Methods
The stability of the PSMD12 protein upon mutation was investigated thermodynamically through the FoldX algorithm (see Results). This study was conducted on the wild-type protein model obtained from the Protein Data Bank [21] . It was mutated in-silico through UCSC Chimera [22] , yielding a second protein model. These values were used to predict the overall protein stability, with and without mutation.
Results
Next generation sequencing revealed a missense variant in heterozygous state in the exon 8 of the PSMD12 gene The variant has been submitted to LOVD (https://databases.lovd.nl/shared/variants/0000478178; patient ID #00234320).
Discussion
In this study, we describe a patient carrier of a missense mutation, the first to date reported in medical literature, of PSMD12, a gene involved in the degradation of proteins by the ubiquitin-proteasome system and recently associated to NDDs. The variant c.866G>C was predicted to be likely pathogenic [20] and involve the high conserved residue p.(Arg289Pro). To date, there have been two separate publications describing postnatal cases with PSMD12 pathogenic variants (point mutations or copy number variations). In Table 1 are summarized and compared the clinical and molecular findings on patients reported to date, including our, with a total of twenty affected patients. The first study which provide a review of copy number variations (CNVs), nonsense variants and splice variant of Although not as common, other clinical features reported are seizure (3/20, 15%) and brain structural anomalies (3/20, 15%) .
Present case
Interesting to note, all patients to date described in medical literature have been identified by whole exome sequencing or whole genome array analysis, suggesting that the phenotype associated with PSMD12 point mutations or microdeletions is not yet easily recognizable. In fact, although facial dysmorphisms were observed in 14/20 (70%), they were variable, tipically very mild or not described in detail. Our patient is the one with the most detailed dysmorphic characterization (elongated and hatchet face, bitemporal hallowing, thick eyebrow with synophrys, down slanting palpebral fissures and eyelids ptosis, long and prominent nasal bridge, low-set and posteriorly rotated ears, high arched palate, triangular chin with micrognathia, webbed neck, low hairline at the back of the neck) ( Figure 1) , and for this reason useful to start defining a typical facial gestalt that addresses the diagnosis. Obviously, additional cases are needed to expand the spectrum of clinical features associated with this emerging syndrome and define the core phenotype that make it recognizable or suspected.
Our patient inherited the genetic variation from the father, who did not underwent to date psychological evaluation of cognitive capability (recommended during genetic counseling). However, the variable expressivity of some genetic alteration is an evidence, not uncommon in NDDs, which represents a great challenge in genetic counselling.
As an example, microdeletions or point mutations of NRXN1, a gene responsible of ASD, ADHD, ID, seizure, schizophrenia can be inherited form apparently healthy parents [23, 24] . It is possible that other polygenic, epigenetic or multifactorial effects such as synergic heterozygosity, modifier gene effect, could play a role in the penetrance and expression of some genetic variants. Obviously, although the variant affects a highly conserved residue and its impact is predicted to be deleterious or likely deleterious by most of the predictors consulted and by in silico modeling, functional studies are needed to confirm these emerging bioinformatics evidences.
The haploinsufficiency of PSMD12 is the mechanism proposed by Küry et al. [10] , and Khalil et al. 
Conclusion
In conclusion, we described the first missense mutation of PSMD12, detected in a patient affected by an emerging syndromic form of NDD. Our finding confirm the recent disease association of PSMD12, expand the molecular spectrum of heterozygous PSMD12 mutations and provide insight into molecular pathogenesis of this new condition. Ascertainment of more cases with PSMD12 mutations is required to further delineate the phenotypic spectrum of PSMD12-related neurodevelopmental disorder.
